Glipizide and Metformin tablets
 Glipizide ER

drug-information.ru

|Glipizide and Metformin tablets Glipizide ER

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Glipizide and Metformin


Generic Name: Glipizide and Metformin hydrochloride)
Dosage Form: Tablets

Glipizide and Metformin Description

Glipizide and Metformin hydrochloride tablets contain two oral antihyperglycemic drugs used in the management of type 2 diabetes, glipizide, USP and metformin hydrochloride.

Glipizide, USP is an oral antihyperglycemic drug of the sulfonylurea class. The chemical name for glipizide is 1-cyclohexyl-3-[[ρ-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl]sulfonyl]urea. Glipizide is a whitish, odorless powder with a molecular formula of C21H27N5O4S, a molecular weight of 445.54 and a pKa of 5.9. It is insoluble in water and alcohols, but soluble in 0.1 N NaOH; it is freely soluble in dimethylformamide. The structural formula is represented below.

Metformin hydrochloride is an oral antihyperglycemic drug used in the management of type 2 diabetes. Metformin hydrochloride (N,N-dimethylimidodicarbonimidic diamide monohydrochloride) is not chemically or pharmacologically related to sulfonylureas, thiazolidinediones, or α-glucosidase inhibitors. It is a white to off-white crystalline compound with a molecular formula of C4H12ClN5 (monohydrochloride) and a molecular weight of 165.63. Metformin hydrochloride is freely soluble in water and is practically insoluble in acetone, ether, and chloroform. The pKa of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68. The structural formula is as shown:

Glipizide and Metformin hydrochloride tablets are available for oral administration in tablets containing 2.5 mg glipizide with 250 mg metformin hydrochloride, 2.5 mg glipizide with 500 mg metformin hydrochloride, and 5 mg glipizide with 500 mg metformin hydrochloride. In addition, each tablet contains the following inactive ingredients: croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, povidone, propylene glycol and titanium dioxide. The 2.5mg/250 mg and 5 mg/500 mg tablets contain iron oxide red as a color additive.

The tablets are film coated, which provides color differentiation.

Glipizide and Metformin - Clinical Pharmacology

Mechanism of Action

Glipizide and Metformin hydrochloride tablets combine Glipizide and Metformin hydrochloride, two antihyperglycemic agents with complementary mechanisms of action, to improve glycemic control in patients with type 2 diabetes.

Glipizide appears to lower blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. Extrapancreatic effects may play a part in the mechanism of action of oral sulfonylurea hypoglycemic drugs. The mechanism by which glipizide lowers blood glucose during long-term administration has not been clearly established. In man, stimulation of insulin secretion by glipizide in response to a meal is undoubtedly of major importance. Fasting insulin levels are not elevated even on long-term glipizide administration, but the postprandial insulin response continues to be enhanced after at least 6 months of treatment.

Metformin hydrochloride is an antihyperglycemic agent that improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

Pharmacokinetics

Absorption and Bioavailability

Glipizide and Metformin hydrochloride tablets

In a single dose study in healthy subjects, the Glipizide and Metformin components of Glipizide and Metformin hydrochloride tablets 5 mg/500 mg were bioequivalent to coadministered glipizide tablets and metformin hydrochloride tablets. Following administration of a single Glipizide and Metformin hydrochloride 5 mg/500 mg tablet in healthy subjects with either a 20% glucose solution or a 20% glucose solution with food, there was a small effect of food on peak plasma concentration (Cmax) and no effect of food on area under the curve (AUC) of the glipizide component. Time to peak plasma concentration (Tmax) for the glipizide component was delayed 1 hour with food relative to the same tablet strength administered fasting with a 20% glucose solution. Cmax for the metformin component was reduced approximately 14% by food whereas AUC was not affected. Tmax for the metformin component was delayed 1 hour after food.

Glipizide

Gastrointestinal absorption of glipizide is uniform, rapid, and essentially complete. Peak plasma concentrations occur 1-3 hours after a single oral dose. Glipizide does not accumulate in plasma on repeated oral administration. Total absorption and disposition of an oral dose was unaffected by food in normal volunteers, but absorption was delayed by about 40 minutes.

Metformin hydrochloride

The absolute bioavailability of a 500 mg metformin hydrochloride tablet given under fasting conditions is approximately 50-60%. Studies using single oral doses of metformin tablets of 500 mg and 1500 mg, and 850 mg to 2550 mg, indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination. Food decreases the extent of and slightly delays the absorption of metformin, as shown by approximately a 40% lower peak concentration and a 25% lower AUC in plasma and a 35-minute prolongation of time to peak plasma concentration following administration of a single 850 mg tablet of metformin with food, compared to the same tablet strength administered fasting. The clinical relevance of these decreases is unknown.

Distribution

Glipizide

Protein binding was studied in serum from volunteers who received either oral or intravenous glipizide and found to be 98-99% one hour after either route of administration. The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment. In mice, no glipizide or metabolites were detectable autoradiographically in the brain or spinal cord of males or females, nor in the fetuses of pregnant females. In another study, however, very small amounts of radioactivity were detected in the fetuses of rats given labeled drug.

Metformin hydrochloride

The apparent volume of distribution (V/F) of metformin following single oral doses of 850 mg averaged 654 ± 358 L. Metformin is negligibly bound to plasma proteins. Metformin partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing schedules of metformin, steady state plasma concentrations of metformin are reached within 24-48 hours and are generally <1 µg/mL. During controlled clinical trials, maximum metformin plasma levels did not exceed 5 µg/mL, even at maximum doses.

Metabolism and Elimination

Glipizide

The metabolism of glipizide is extensive and occurs mainly in the liver. The primary metabolites are inactive hydroxylation products and polar conjugates and are excreted mainly in the urine. Less than 10% unchanged glipizide is found in the urine. The half-life of elimination ranges from 2-4 hours in normal subjects, whether given intravenously or orally. The metabolic and excretory patterns are similar with the two routes of administration, indicating that first-pass metabolism is not significant.

Metformin hydrochloride

Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion. Renal clearance (see Table 1) is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.

Special Populations

Patients with Type 2 Diabetes

In the presence of normal renal function, there are no differences between single- or multiple-dose pharmacokinetics of metformin between patients with type 2 diabetes and normal subjects (see Table 1), nor is there any accumulation of metformin in either group at usual clinical doses.

Hepatic Insufficiency

The metabolism and excretion of glipizide may be slowed in patients with impaired hepatic function (see PRECAUTIONS). No pharmacokinetic studies have been conducted in patients with hepatic insufficiency for metformin.

Renal Insufficiency

The metabolism and excretion of glipizide may be slowed in patients with impaired renal function (see PRECAUTIONS).

In patients with decreased renal function (based on creatinine clearance), the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased in proportion to the decrease in creatinine clearance (see Table 1; also, see WARNINGS).

Geriatrics

There is no information on the pharmacokinetics of glipizide in elderly patients.

Limited data from controlled pharmacokinetic studies of metformin in healthy elderly subjects suggest that total plasma clearance is decreased, the half-life is prolonged, and Cmax is increased, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function (see Table 1). Metformin treatment should not be initiated in patients ≥ 80 years of age unless measurement of creatinine clearance demonstrates that renal function is not reduced.

Table 1: Select Mean (±S.D.) Metformin Pharmacokinetic Parameters Following
Single or Multiple Oral Doses of Metformin
Subject Groups: Metformin
Dose* (number of subjects)
Cmax
(µg/mL)
Tmax
(hrs)
Renal Clearance
( mL/min)
*
All doses given fasting except the first 18 doses of the multiple-dose studies
Peak plasma concentration
Time to peak plasma concentration
§
SD=single dose
Combined results (average means) of five studies: mean age 32 years (range 23-59 years)
#
Kinetic study done following dose 19, given fasting
Þ
Elderly subjects, mean age 71 years (range 65-81 years)
ß
CLcr = creatinine clearance normalized to body surface area of 1.73 m2
Healthy, Nondiabetic Adults:
  500 mg SD§ (24)
  850 mg SD (74)
  850 mg t.i.d. for 19 doses# (9)
1.03 (±0.33)
1.60 (±0.38)
2.01 (±0.42)
2.75 (±0.81)
2.64 (±0.82)
1.79 (±0.94)
600 (±132)
552 (±139)
642 (±173)
Adults with Type 2 Diabetes:
  850 mg SD (23)
  850 mg t.i.d. for 19 doses#(9)
1.48 (±0.5)
1.90 (±0.62)
3.32 (±1.08)
2.01 (±1.22)
491 (±138)
550 (±160)
ElderlyÞ Healthy Nondiabetic Adults:
  850 mg SD (12)
2.45 (±0.70) 2.71 (±1.05) 412 (±98)
Renal-impaired Adults: 850 mg SD
  Mild (CLcrß 61-90 mL/min) (5)
  Moderate (CLcr 31-60 mL/min) (4)
  Severe (CLcr 10-30 mL/min) (6)
1.86 (±0.52)
4.12 (±1.83)
3.93 (±0.92)
3.20 (±0.45)
3.75 (±0.50)
4.01 (±1.10)
384 (±122)
108 (±57)
130 (±90)

Pediatrics

No data from pharmacokinetic studies in pediatric subjects are available for either glipizide or metformin.

Gender

There is no information on the effect of gender on the pharmacokinetics of glipizide.

Metformin pharmacokinetic parameters did not differ significantly in subjects with or without type 2 diabetes when analyzed according to gender (males=19, females=16). Similarly, in controlled clinical studies in patients with type 2 diabetes, the antihyperglycemic effect of metformin was comparable in males and females.

Race

No information is available on race differences in the pharmacokinetics of glipizide.

No studies of metformin pharmacokinetic parameters according to race have been performed. In controlled clinical studies of metformin in patients with type 2 diabetes, the antihyperglycemic effect was comparable in whites (n=249), blacks (n=51), and Hispanics (n=24).

Clinical Studies

Initial Therapy

In a 24-week, double-blind, active-controlled, multicenter international clinical trial, patients with type 2 diabetes, whose hyperglycemia was not adequately controlled with diet and exercise alone (hemoglobin A1c [HbA1c]>7.5% and ≤ 12% and fasting plasma glucose [FPG]<300 mg/dL) were randomized to receive initial therapy with glipizide 5 mg, metformin 500 mg, Glipizide and Metformin hydrochloride 2.5 mg/250 mg, or Glipizide and Metformin hydrochloride 2.5 mg/500 mg. After two weeks, the dose was progressively increased (up to the 12-week visit) to a maximum of four tablets daily in divided doses as needed to reach a target mean daily glucose (MDG) of ≤ 130 mg/dL. Trial data at 24 weeks are summarized in Table 2.

Table 2: Active-Controlled Trial of Glipizide and Metformin Hydrochloride
Tablets as Initial Therapy:
Summary of Trial Data at 24 Weeks
Glipizide
5 mg
tablets
Metformin
500 mg
tablets
Glipizide and
Metformin
Hydrochloride
2.5 mg/250 mg
tablets
Glipizide and
Metformin
Hydrochloride
2.5 mg/500 mg
tablets
*
p<0.001
Mean Final Dose 16.7 mg 1749 mg 7.9 mg/791 mg 7.4 mg/1477 mg
Hemoglobin A1c(%) N = 168 N = 171 N = 166 N = 163
  Baseline Mean 9.17 9.15 9.06 9.10
  Final Mean 7.36 7.67 6.93 6.95
  Adjusted Mean
  Change from Baseline
-1.77 -1.46 -2.15 -2.14
  Difference from Glipizide -0.38* -0.37*
  Difference from Metformin -0.70* -0.69*
  % Patients with Final HbA1c>7% 43.5% 35.1% 59.6% 57.1%
Fasting Plasma Glucose (mg/dL) N = 169 N = 176 N = 170 N = 169
  Baseline Mean 210.7 207.4 206.8 203.1
  Final Mean 162.1 163.8 152.1 148.7
  Adjusted Mean Change
  from Baseline
-46.2 -42.9 -54.2 -56.5
  Difference from Glipizide -8.0 -10.4
  Difference from Metformin -11.3 -13.6

After 24 weeks, treatment with Glipizide and Metformin hydrochloride 2.5 mg/250 mg and 2.5 mg/500 mg resulted in significantly greater reduction in HbA1c compared to glipizide and to metformin therapy. Also, Glipizide and Metformin hydrochloride 2.5 mg/250 mg therapy resulted in significant reductions in FPG versus metformin therapy.

Increases above fasting glucose and insulin levels were determined at baseline and final study visits by measurement of plasma glucose and insulin for three hours following a standard mixed liquid meal. Treatment with Glipizide and Metformin hydrochloride lowered the three-hour postprandial glucose AUC, compared to baseline, to a significantly greater extent than did the glipizide and the metformin therapies. Compared to baseline, Glipizide and Metformin hydrochloride enhanced the postprandial insulin response, but did not significantly affect fasting insulin levels.

There were no clinically meaningful differences in changes from baseline for all lipid parameters between Glipizide and Metformin hydrochloride therapy and either metformin therapy or glipizide therapy. The adjusted mean changes from baseline in body weight were: Glipizide and Metformin hydrochloride 2.5 mg/250 mg, -0.4 kg; Glipizide and Metformin hydrochloride 2.5 mg/500 mg, -0.5 kg; glipizide, -0.2 kg; and metformin, -1.9 kg. Weight loss was greater with metformin than with Glipizide and Metformin hydrochloride.

Second-Line Therapy

In an 18-week, double-blind, active-controlled U.S. clinical trial, a total of 247 patients with type 2 diabetes not adequately controlled (HbA1c≥ 7.5% and ≤ 12% and FPG <300 mg/dL) while being treated with at least one-half the maximum labeled dose of a sulfonylurea (e.g., glyburide 10 mg, glipizide 20 mg) were randomized to receive glipizide (fixed dose, 30 mg), metformin (500 mg), or Glipizide and Metformin hydrochloride 5 mg/500 mg. The doses of metformin and Glipizide and Metformin hydrochloride were titrated (up to the eight-week visit) to a maximum of four tablets daily as needed to achieve MDG ≤ 130 mg/dL. Trial data at 18 weeks are summarized in Table 3.

Table 3: Glipizide and Metformin Hydrochloride Tablets as Second-Line
Therapy: Summary of Trial Data at 18 Weeks
Glipizide
5 mg
tablets
Metformin
500 mg
tablets
Glyburide and
Metformin
Hydrochloride
5 mg/500 mg tablets
*
p < 0.001
Mean Final Dose 30.0 mg 1927 mg 17.5 mg/1747 mg
Hemoglobin A1c(%) N = 79 N = 71 N = 80
  Baseline Mean 8.87 8.61 8.66
  Final Adjusted Mean 8.45 8.36 7.39
  Difference from Glipizide -1.06*
  Difference from Metformin -0.98*
  % Patients with Final HbA1c<7% 8.9% 9.9% 36.3%
Fasting Plasma Glucose (mg/dL) N = 82 N = 75 N = 81
  Baseline Mean 203.6 191.3 194.3
  Adjusted Mean Change
  from Baseline
7.0 6.7 -30.4
  Difference from Glipizide -37.4
  Difference from Metformin -37.2

After 18 weeks, treatment with Glipizide and Metformin hydrochloride at doses up to 20 mg/2000 mg per day resulted in significantly lower mean final HbA1c and significantly greater mean reductions in FPG compared to glipizide and to metformin therapy. Treatment with Glipizide and Metformin hydrochloride lowered the three-hour postprandial glucose AUC, compared to baseline, to a significantly greater extent than did the glipizide and the metformin therapies. Glipizide and Metformin hydrochloride did not significantly affect fasting insulin levels.

There were no clinically meaningful differences in changes from baseline for all lipid parameters between Glipizide and Metformin hydrochloride therapy and either metformin therapy or glipizide therapy. The adjusted mean changes from baseline in body weight were: Glipizide and Metformin hydrochloride 5 mg/500 mg, -0.3 kg; glipizide, -0.4 kg; and metformin, -2.7 kg. Weight loss was greater with metformin than with Glipizide and Metformin hydrochloride.

INDICATIONS AND USAGE

Glipizide and Metformin hydrochloride tablets are indicated as initial therapy, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes whose hyperglycemia cannot be satisfactorily managed with diet and exercise alone.

Glipizide and Metformin hydrochloride tablets are indicated as second-line therapy when diet, exercise, and initial treatment with a sulfonylurea or metformin do not result in adequate glycemic control in patients with type 2 diabetes.

CONTRAINDICATIONS

Glipizide and Metformin hydrochloride tablets are contraindicated in patients with:

  1. Renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥ 1.5 mg/dL [males], ≥ 1.4 mg/dL [females], or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see WARNINGS and PRECAUTIONS).
  2. Congestive heart failure requiring pharmacologic treatment.
  3. Known hypersensitivity to glipizde or metformin hydrochloride.
  4. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Diabetic ketoacidosis should be treated with insulin.

Glipizide and Metformin hydrochloride tablets should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function. (See also PRECAUTIONS.)

WARNINGS

Metformin Hydrochloride

Lactic acidosis:

Lactic acidosis is a rare, but serious, metabolic complication that can occur due to metformin accumulation during treatment with Glipizide and Metformin hydrochloride; when it occurs, it is fatal in approximately 50% of cases. Lactic acidosis may also occur in association with a number of pathophysiologic conditions, including diabetes mellitus, and whenever there is significant tissue hypoperfusion and hypoxemia. Lactic acidosis is characterized by elevated blood lactate levels (>5 mmol/L), decreased blood pH, electrolyte disturbances with an increased anion gap, and an increased lactate/pyruvate ratio. When metformin is implicated as the cause of lactic acidosis, metformin plasma levels >5 µg/mL are generally found.

The reported incidence of lactic acidosis in patients receiving metformin hydrochloride is very low (approximately 0.03 cases/1000 patient-years, with approximately 0.015 fatal cases/1000 patient-years). Reported cases have occurred primarily in diabetic patients with significant renal insufficiency, including both intrinsic renal disease and renal hypoperfusion, often in the setting of multiple concomitant medical/surgical problems and multiple concomitant medications. Patients with congestive heart failure requiring pharmacologic management, in particular those with unstable or acute congestive heart failure who are at risk of hypoperfusion and hypoxemia, are at increased risk of lactic acidosis. The risk of lactic acidosis increases with the degree of renal dysfunction and the patient"s age. The risk of lactic acidosis may, therefore, be significantly decreased by regular monitoring of renal function in patients taking metformin and by use of the minimum effective dose of metformin. In particular, treatment of the elderly should be accompanied by careful monitoring of renal function. Glipizide and Metformin hydrochloride treatment should not be initiated in patients ≥ 80 years of age unless measurement of creatinine clearance demonstrates that renal function is not reduced, as these patients are more susceptible to developing lactic acidosis. In addition, Glipizide and Metformin hydrochloride should be promptly withheld in the presence of any condition associated with hypoxemia, dehydration, or sepsis. Because impaired hepatic function may significantly limit the ability to clear lactate, Glipizide and Metformin hydrochloride should generally be avoided in patients with clinical or laboratory evidence of hepatic disease. Patients should be cautioned against excessive alcohol intake, either acute or chronic, when taking Glipizide and Metformin hydrochloride, since alcohol potentiates the effects of metformin hydrochloride on lactate metabolism. In addition, Glipizide and Metformin hydrochloride should be temporarily discontinued prior to any intravascular radiocontrast study and for any surgical procedure (see also PRECAUTIONS).

The onset of lactic acidosis often is subtle, and accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and nonspecific abdominal distress. There may be associated hypothermia, hypotension, and resistant bradyarrhythmias with more marked acidosis. The patient and the patient"s physician must be aware of the possible importance of such symptoms and the patient should be instructed to notify the physician immediately if they occur (see also PRECAUTIONS). Glipizide and Metformin hydrochloride should be withdrawn until the situation is clarified. Serum electrolytes, ketones, blood glucose, and if indicated, blood pH, lactate levels, and even blood metformin levels may be useful. Once a patient is stabilized on any dose level of Glipizide and Metformin hydrochloride, gastrointestinal symptoms, which are common during initiation of therapy with metformin, are unlikely to be drug related. Later occurrence of gastrointestinal symptoms could be due to lactic acidosis or other serious disease.

Levels of fasting venous plasma lactate above the upper limit of normal but less than 5 mmol/L in patients taking Glipizide and Metformin hydrochloride do not necessarily indicate impending lactic acidosis and may be explainable by other mechanisms, such as poorly controlled diabetes or obesity, vigorous physical activity, or technical problems in sample handling. (See also PRECAUTIONS.)

Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).

Lactic acidosis is a medical emergency that must be treated in a hospital setting. In a patient with lactic acidosis who is taking Glipizide and Metformin hydrochloride, the drug should be discontinued immediately and general supportive measures promptly instituted. Because metformin hydrochloride is dialyzable (with a clearance of up to 170 mL/min under good hemodynamic conditions), prompt hemodialysis is recommended to correct the acidosis and remove the accumulated metformin. Such management often results in prompt reversal of symptoms and recovery. (See also CONTRAINDICATIONS and PRECAUTIONS.)

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY

The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (Diabetes 19 (Suppl. 2):747-830, 1970).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2½ times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and benefits of glipizide and of alternative modes of therapy.

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

Precautions

General

Glipizide and Metformin Hydrochloride Tablets

Hypoglycemia  -  Glipizide and Metformin hydrochloride tablets are capable of producing hypoglycemia, therefore, proper patient selection, dosing, and instructions are important to avoid potential hypoglycemic episodes. The risk of hypoglycemia is increased when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents or ethanol. Renal insufficiency may cause elevated drug levels of both Glipizide and Metformin hydrochloride. Hepatic insufficiency may increase drug levels of glipizide and may also diminish gluconeogenic capacity, both of which increase the risk of hypoglycemic reactions. Elderly, debilitated, or malnourished patients and those with adrenal or pituitary insufficiency or alcohol intoxication are particularly susceptible to hypoglycemic effects. Hypoglycemia may be difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs.

Glipizide

Renal and hepatic disease - The metabolism and excretion of glipizide may be slowed in patients with impaired renal and/or hepatic function. If hypoglycemia should occur in such patients, it may be prolonged and appropriate management should be instituted.

Metformin Hydrochloride

Monitoring of renal function - Metformin is known to be substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Thus, patients with serum creatinine levels above the upper limit of normal for their age should not receive Glipizide and Metformin hydrochloride. In patients with advanced age, Glipizide and Metformin hydrochloride should be carefully titrated to establish the minimum dose for adequate glycemic effect, because aging is associated with reduced renal function. In elderly patients, particularly those > 80 years of age, renal function should be monitored regularly and, generally, Glipizide and Metformin hydrochloride should not be titrated to the maximum dose (see WARNINGS and DOSAGE AND ADMINISTRATION). Before initiation of Glipizide and Metformin hydrochloride therapy and at least annually thereafter, renal function should be assessed and verified as normal. In patients in whom development of renal dysfunction is anticipated, renal function should be assessed more frequently and Glipizide and Metformin hydrochloride discontinued if evidence of renal impairment is present.

Concomitant medications that may affect renal function or metformin disposition - Concomitant medication(s) that may affect renal function or result in significant hemodynamic change or may interfere with the disposition of metformin, such as cationic drugs that are eliminated by renal tubular secretion (see PRECAUTIONS: Drug Interactions), should be used with caution.

Radiologic studies involving the use of intravascular iodinated contrast materials (for example, intravenous urogram, intravenous cholangiography, angiography, and computed tomography (CT) scans with intravascular contrast materials) - Intravascular contrast studies with iodinated materials can lead to acute alteration of renal function and have been associated with lactic acidosis in patients receiving metformin (see CONTRAINDICATIONS). Therefore, in patients in whom any such study is planned, Glipizide and Metformin hydrochloride should be temporarily discontinued at the time of or prior to the procedure, and withheld for 48 hours subsequent to the procedure and reinstituted only after renal function has been reevaluated and found to be normal.

Hypoxic states - Cardiovascular collapse (shock) from whatever cause, acute congestive heart failure, acute myocardial infarction, and other conditions characterized by hypoxemia have been associated with lactic acidosis and may also cause pre-renal azotemia. When such events occur in patients on glyburide and metformin hydrochloride therapy, the drug should be promptly discontinued.

Surgical procedures - Glipizide and Metformin hydrochloride therapy should be temporarily suspended for any surgical procedure (except minor procedures not associated with restricted intake of food and fluids) and should not be restarted until the patient’s oral intake has resumed and renal function has been evaluated as normal.

Alcohol intake - Alcohol is known to potentiate the effect of metformin on lactate metabolism. Patients, therefore, should be warned against excessive alcohol intake, acute or chronic, while receiving Glipizide and Metformin hydrochloride tablets. Due to its effect on the gluconeogenic capacity of the liver, alcohol may also increase the risk of hypoglycemia

Impaired hepatic function - Since impaired hepatic function has been associated with some cases of lactic acidosis, Glipizide and Metformin hydrochloride should generally be avoided in patients with clinical or laboratory evidence of hepatic disease

Vitamin B12 levels - In controlled clinical trials with metformin of 29 weeks duration, a decrease to subnormal levels of previously normal serum Vitamin B12, without clinical manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to interference with B12 absorption from the B12 -intrinsic factor complex, is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of metformin or Vitamin B12 supplementation. Measurement of hematologic parameters on an annual basis is advised in patients on metformin and any apparent abnormalities should be appropriately investigated and managed (see PRECAUTIONS: Laboratory Tests ).

Certain individuals (those with inadequate Vitamin B12 or calcium intake or absorption) appear to be predisposed to developing subnormal Vitamin B12 levels. In these patients, routine serum Vitamin B12 measurements at two- to three-year intervals may be useful.

Change in clinical status of patients with previously controlled type 2 diabetes - A patient with type 2 diabetes previously well controlled on metformin who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate, and metformin levels. If acidosis of either form occurs, Glipizide and Metformin hydrochloride must be stopped immediately and other appropriate corrective measures initiated (see also WARNINGS).

Information for Patients

Glipizide and Metformin Hydrochloride Tablets

Patients should be informed of the potential risks and benefits of Glipizide and Metformin hydrochloride and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose, glycosylated hemoglobin, renal function, and hematologic parameters.

The risks of lactic acidosis associated with metformin therapy, its symptoms, and conditions that predispose to its development, as noted in the WARNINGS and PRECAUTIONS sections, should be explained to patients. Patients should be advised to discontinue Glipizide and Metformin hydrochloride immediately and to promptly notify their health practitioner if unexplained hyperventilation, myalgia, malaise, unusual somnolence, or other nonspecific symptoms occur. Once a patient is stabilized on any dose level of Glipizide and Metformin hydrochloride, gastrointestinal symptoms, which are common during initiation of metformin therapy, are unlikely to be drug related. Later occurrence of gastrointestinal symptoms could be due to lactic acidosis or other serious disease.

The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members.

Patients should be counseled against excessive alcohol intake, either acute or chronic, while receiving Glipizide and Metformin hydrochloride tablets. (See Patient Information printed below.)

Laboratory Tests

Periodic fasting blood glucose and glycosylated hemoglobin (HbA1c) measurements should be performed to monitor therapeutic response.

Initial and periodic monitoring of hematologic parameters (e.g., hemoglobin/hematocrit and red blood cell indices) and renal function (serum creatinine) should be performed, at least on an annual basis. While megaloblastic anemia has rarely been seen with metformin therapy, if this is suspected, Vitamin B12 deficiency should be excluded.

Drug Interactions

Glipizide and Metformin Hydrochloride Tablets

Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin hydrochloride, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin hydrochloride, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins.

Glipizide

The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving Glipizide and Metformin hydrochloride, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving Glipizide and Metformin hydrochloride, the patient should be observed closely for loss of blood glucose control. In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to the clinical situation and in the use of Glipizide and Metformin hydrochloride with these drugs.

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known. The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers. All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single oral daily dose for 7 days, the mean percent increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81%).

Metformin Hydrochloride

Furosemide  -  A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide increased the metformin plasma and blood Cmax by 22% and blood AUC by 15%, without any significant change in metformin renal clearance. When administered with metformin, the Cmax and AUC of furosemide were 31% and 12% smaller, respectively, than when administered alone, and the terminal half-life was decreased by 32%, without any significant change in furosemide renal clearance. No information is available about the interaction of metformin and furosemide when co-administered chronically.

Nifedipine  -  A single-dose, metformin-nifedipine drug interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount excreted in the urine. Tmax and half-life were unaffected. Nifedipine appears to enhance the absorption of metformin. Metformin had minimal effects on nifedipine.

Cationic drugs  -  Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. Such interaction between metformin and oral cimetidine has been observed in normal healthy volunteers in both single- and multiple-dose, metformin-cimetidine drug interaction studies, with a 60% increase in peak metformin plasma and whole blood concentrations and a 40% increase in plasma and whole blood metformin AUC. There was no change in elimination half-life in the single-dose study. Metformin had no effect on cimetidine pharmacokinetics. Although such interactions remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of Glipizide and Metformin hydrochloride tablets and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.

Other  -  In healthy volunteers, the pharmacokinetics of metformin and propranolol and metformin and ibuprofen were not affected when co-administered in single-dose interaction studies.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No animal studies have been conducted with the combined products in Glipizide and Metformin hydrochloride. The following data are based on findings in studies performed with the individual products.

Glipizide

A 20-month study in rats and an 18-month study in mice at doses up to 75 times the maximum human dose revealed no evidence of drug-related carcinogenicity. Bacterial and in vivo mutagenicity tests were uniformly negative. Studies in rats of both sexes at doses up to 75 times the human dose showed no effects on fertility.

Metformin Hydrochloride

Long-term carcinogenicity studies were performed with metformin alone in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1500 mg/kg/day, respectively. These doses are both approximately four times the maximum recommended human daily dose of 2000 mg of the metformin component of Glipizide and Metformin hydrochloride tablets based on body surface area comparisons. No evidence of carcinogenicity with metformin alone was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin alone in male rats. There was, however, an increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day of metformin alone.

There was no evidence of a mutagenic potential of metformin alone in the following in vitro tests: Ames test (S. typhimurium), gene mutation test (mouse lymphoma cells), or chromosomal aberrations test (human lymphocytes). Results in the in vivo mouse micronucleus test were also negative.

Fertility of male or female rats was unaffected by metformin alone when administered at doses as high as 600 mg/kg/day, which is approximately three times the maximum recommended human daily dose of the metformin component of Glipizide and Metformin hydrochloride tablets based on body surface area comparisons.

Pregnancy

Teratogenic Effects: Pregnancy Category C

Recent information strongly suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities. Most experts recommend that insulin be used during pregnancy to maintain blood glucose as close to normal as possible. Because animal reproduction studies are not always predictive of human response, Glipizide and Metformin hydrochloride tablets should not be used during pregnancy unless clearly needed. (See below.)

There are no adequate and well-controlled studies in pregnant women with Glipizide and Metformin hydrochloride tablets or its individual components. No animal studies have been conducted with the combined products in Glipizide and Metformin hydrochloride tablets. The following data are based on findings in studies performed with the individual products.

Glipizide

Glipizide was found to be mildly fetotoxic in rat reproductive studies at all dose levels (5-50 mg/kg). This fetotoxicity has been similarly noted with other sulfonylureas, such as tolbutamide and tolazamide. The effect is perinatal and believed to be directly related to the pharmacologic (hypoglycemic) action of glipizide. In studies in rats and rabbits, no teratogenic effects were found.

Metformin hydrochloride

Metformin alone was not teratogenic in rats or rabbits at doses up to 600 mg/kg/day. This represents an exposure of about two and six times the maximum recommended human daily dose of 2000 mg of the metformin component of Glipizide and Metformin hydrochloride tablets based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.

Nonteratogenic Effects

Prolonged severe hypoglycemia (4 to 10 days) has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. This has been reported more frequently with the use of agents with prolonged half-lives. It is not recommended that Glipizide and Metformin hydrochloride tablets be used during pregnancy. However, if it is used, Glipizide and Metformin hydrochloride tablets should be discontinued at least one month before the expected delivery date. (See Pregnancy; Teratogenic Effects: Pregnancy Category C.)

Nursing Mothers

Although it is not known whether glipizide is excreted in human milk, some sulfonylurea drugs are known to be excreted in human milk. Studies in lactating rats show that metformin is excreted into milk and reaches levels comparable to those in plasma. Similar studies have not been conducted in nursing mothers. Because the potential for hypoglycemia in nursing infants may exist, a decision should be made whether to discontinue nursing or to discontinue Glipizide and Metformin hydrochloride tablets, taking into account the importance of the drug to the mother. If Glipizide and Metformin hydrochloride tablets are discontinued, and if diet alone is inadequate for controlling blood glucose, insulin therapy should be considered.

Pediatric Use

Safety and effectiveness of Glipizide and Metformin hydrochloride tablets in pediatric patients have not been established.

Geriatric Use

Of the 345 patients who received Glipizide and Metformin hydrochloride 2.5 mg/250 mg and 2.5 mg/500 mg in the initial therapy trial, 67 (19.4%) were aged 65 and older while 5 (1.4%) were aged 75 and older. Of the 87 patients who received Glipizide and Metformin hydrochloride in the second-line therapy trial, 17 (19.5%) were aged 65 and older while one (1.1%) was at least aged 75. No overall differences in effectiveness or safety were observed between these patients and younger patients in either the initial therapy trial or the second-line therapy trial, and other reported clinical experience has not identified differences in response between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Metformin hydrochloride is known to be substantially excreted by the kidney and because the risk of serious adverse reactions to the drug is greater in patients with impaired renal function, Glipizide and Metformin hydrochloride tablets should only be used in patients with normal renal function (see CONTRAINDICATIONS, WARNINGS, and CLINICAL PHARMACOLOGY: Pharmacokinetics). Because aging is associated with reduced renal function, Glipizide and Metformin hydrochloride should be used with caution as age increases. Care should be taken in dose selection and should be based on careful and regular monitoring of renal function. Generally, elderly patients should not be titrated to the maximum dose of Glipizide and Metformin hydrochloride (see also WARNINGS and DOSAGE AND ADMINISTRATION).

Adverse Reactions

Glipizide and Metformin Hydrochloride Tablets

In a double-blind 24-week clinical trial involving Glipizide and Metformin hydrochloride tablets as initial therapy, a total of 172 patients received Glipizide and Metformin hydrochloride 2.5 mg/250 mg, 173 received Glipizide and Metformin hydrochloride 2.5 mg/500 mg, 170 received glipizide, and 177 received metformin. The most common clinical adverse events in these treatment groups are listed in Table 4.

Table 4: Clinical Adverse Events >5% in any Treatment Group,
by Primary Term, in Initial Therapy Study
Adverse Event Number (%) of Patients
Glipizide
5 mg
tablets
N=170
Metformin
500 mg
tablets
N=177
Glipizide and
Metformin
Hydrochloride
2.5 mg/250 mg
tablets
N=172
Glipizide and
Metformin
Hydrochloride
2.5 mg/500 mg
tablets
N=173
Upper respiratory
infection
12 (7.1) 15 (8.5) 17 (9.9) 14 (8.1)
Diarrhea 8 (4.7) 15 (8.5) 4 (2.3) 9 (5.2)
Dizziness 9 (5.3) 2 (1.1) 3 (1.7) 9 (5.2)
Hypertension 17 (10.0) 10 (5.6) 5 (2.9) 6 (3.5)
Nausea/vomiting 6 (3.5) 9 (5.1) 1 (0.6) 3 (1.7)

In a double-blind 18-week clinical trial involving Glipizide and Metformin hydrochloride tablets as second-line therapy, a total of 87 patients received Glipizide and Metformin hydrochloride, 84 received glipizide, and 75 received metformin. The most common clinical adverse events in this clinical trial are listed in Table 5.

Table 5: Clinical Adverse Events >5% in any Treatment Group,
by Primary Term, in Second-line Therapy Study
Adverse Event Number (%) of Patients
Glipizide
5 mg tablets*
N=84
Metformin
500 mg tablets*
N=75
Glipizide and
Metformin
Hydrochloride
5 mg/500 mg tablets*
N=87
*
The dose of glipizide was fixed at 30 mg daily; doses of metformin and Glipizide and Metformin hydrochloride were titrated. 
Diarrhea 11 (13.1) 13 (17.3) 16 (18.4)
Headache 5 (6.0) 4 (5.3) 11 (12.6)
Upper respiratory infection 11 (13.1) 8 (10.7) 9 (10.3)
Musculoskeletal pain 6 (7.1) 5 (6.7) 7 (8.0)
Nausea/vomiting 5 (6.0) 6 (8.0) 7 (8.0)
Abdominal pain 7 (8.3) 5 (6.7) 5 (5.7)
UTI 4 (4.8) 6 (8.0) 1 (1.1)

Hypoglycemia

In a controlled initial therapy trial of Glipizide and Metformin hydrochloride 2.5 mg/250 mg and 2.5 mg/500 mg the numbers of patients with hypoglycemia documented by symptoms (such as dizziness, shakiness, sweating, and hunger) and a fingerstick blood glucose measurement ≤ 50 mg/dL were 5 (2.9%) for glipizide, 0 (0%) for metformin, 13 (7.6%) for Glipizide and Metformin hydrochloride 2.5 mg/250 mg, and 16 (9.3%) for Glipizide and Metformin hydrochloride 2.5 mg/500 mg. Among patients taking either Glipizide and Metformin hydrochloride 2.5 mg/250 mg or Glipizide and Metformin hydrochloride 2.5 mg/500 mg, nine (2.6%) patients discontinued Glipizide and Metformin hydrochloride tablets due to hypoglycemic symptoms and one required medical intervention due to hypoglycemia. In a controlled second-line therapy trial of Glipizide and Metformin hydrochloride 5 mg/500 mg, the numbers of patients with hypoglycemia documented by symptoms and a fingerstick blood glucose measurement ≤ 50 mg/dL were 0 (0%) for glipizide, 1 (1.3%) for metformin, and 11 (12.6%) for Glipizide and Metformin hydrochloride. One (1.1%) patient discontinued Glipizide and Metformin hydrochloride therapy due to hypoglycemic symptoms and none required medical intervention due to hypoglycemia. (See


Where can I get more information about Glipizide and Metformin tablets Glipizide ER ? We recommend to use www.Drugs.com


Typical mistypes for Glipizide and Metformin tablets Glipizide ER
flipizide and metformin tablets glipizide er, vlipizide and metformin tablets glipizide er, blipizide and metformin tablets glipizide er, hlipizide and metformin tablets glipizide er, ylipizide and metformin tablets glipizide er, tlipizide and metformin tablets glipizide er, gkipizide and metformin tablets glipizide er, gpipizide and metformin tablets glipizide er, goipizide and metformin tablets glipizide er, glupizide and metformin tablets glipizide er, gljpizide and metformin tablets glipizide er, glkpizide and metformin tablets glipizide er, glopizide and metformin tablets glipizide er, gl9pizide and metformin tablets glipizide er, gl8pizide and metformin tablets glipizide er, glioizide and metformin tablets glipizide er, glilizide and metformin tablets glipizide er, gli-izide and metformin tablets glipizide er, gli0izide and metformin tablets glipizide er, glipuzide and metformin tablets glipizide er, glipjzide and metformin tablets glipizide er, glipkzide and metformin tablets glipizide er, glipozide and metformin tablets glipizide er, glip9zide and metformin tablets glipizide er, glip8zide and metformin tablets glipizide er, glipixide and metformin tablets glipizide er, glipiside and metformin tablets glipizide er, glipiaide and metformin tablets glipizide er, glipizude and metformin tablets glipizide er, glipizjde and metformin tablets glipizide er, glipizkde and metformin tablets glipizide er, glipizode and metformin tablets glipizide er, glipiz9de and metformin tablets glipizide er, glipiz8de and metformin tablets glipizide er, glipizise and metformin tablets glipizide er, glipizixe and metformin tablets glipizide er, glipizice and metformin tablets glipizide er, glipizife and metformin tablets glipizide er, glipizire and metformin tablets glipizide er, glipiziee and metformin tablets glipizide er, glipizidw and metformin tablets glipizide er, glipizids and metformin tablets glipizide er, glipizidd and metformin tablets glipizide er, glipizidr and metformin tablets glipizide er, glipizid4 and metformin tablets glipizide er, glipizid3 and metformin tablets glipizide er, glipizide znd metformin tablets glipizide er, glipizide snd metformin tablets glipizide er, glipizide wnd metformin tablets glipizide er, glipizide qnd metformin tablets glipizide er, glipizide abd metformin tablets glipizide er, glipizide amd metformin tablets glipizide er, glipizide ajd metformin tablets glipizide er, glipizide ahd metformin tablets glipizide er, glipizide ans metformin tablets glipizide er, glipizide anx metformin tablets glipizide er, glipizide anc metformin tablets glipizide er, glipizide anf metformin tablets glipizide er, glipizide anr metformin tablets glipizide er, glipizide ane metformin tablets glipizide er, glipizide and netformin tablets glipizide er, glipizide and ketformin tablets glipizide er, glipizide and jetformin tablets glipizide er, glipizide and mwtformin tablets glipizide er, glipizide and mstformin tablets glipizide er, glipizide and mdtformin tablets glipizide er, glipizide and mrtformin tablets glipizide er, glipizide and m4tformin tablets glipizide er, glipizide and m3tformin tablets glipizide er, glipizide and merformin tablets glipizide er, glipizide and mefformin tablets glipizide er, glipizide and megformin tablets glipizide er, glipizide and meyformin tablets glipizide er, glipizide and me6formin tablets glipizide er, glipizide and me5formin tablets glipizide er, glipizide and metdormin tablets glipizide er, glipizide and metcormin tablets glipizide er, glipizide and metvormin tablets glipizide er, glipizide and metgormin tablets glipizide er, glipizide and mettormin tablets glipizide er, glipizide and metrormin tablets glipizide er, glipizide and metfirmin tablets glipizide er, glipizide and metfkrmin tablets glipizide er, glipizide and metflrmin tablets glipizide er, glipizide and metfprmin tablets glipizide er, glipizide and metf0rmin tablets glipizide er, glipizide and metf9rmin tablets glipizide er, glipizide and metfoemin tablets glipizide er, glipizide and metfodmin tablets glipizide er, glipizide and metfofmin tablets glipizide er, glipizide and metfotmin tablets glipizide er, glipizide and metfo5min tablets glipizide er, glipizide and metfo4min tablets glipizide er, glipizide and metfornin tablets glipizide er, glipizide and metforkin tablets glipizide er, glipizide and metforjin tablets glipizide er, glipizide and metformun tablets glipizide er, glipizide and metformjn tablets glipizide er, glipizide and metformkn tablets glipizide er, glipizide and metformon tablets glipizide er, glipizide and metform9n tablets glipizide er, glipizide and metform8n tablets glipizide er, glipizide and metformib tablets glipizide er, glipizide and metformim tablets glipizide er, glipizide and metformij tablets glipizide er, glipizide and metformih tablets glipizide er, glipizide and metformin rablets glipizide er, glipizide and metformin fablets glipizide er, glipizide and metformin gablets glipizide er, glipizide and metformin yablets glipizide er, glipizide and metformin 6ablets glipizide er, glipizide and metformin 5ablets glipizide er, glipizide and metformin tzblets glipizide er, glipizide and metformin tsblets glipizide er, glipizide and metformin twblets glipizide er, glipizide and metformin tqblets glipizide er, glipizide and metformin tavlets glipizide er, glipizide and metformin tanlets glipizide er, glipizide and metformin tahlets glipizide er, glipizide and metformin taglets glipizide er, glipizide and metformin tabkets glipizide er, glipizide and metformin tabpets glipizide er, glipizide and metformin taboets glipizide er, glipizide and metformin tablwts glipizide er, glipizide and metformin tablsts glipizide er, glipizide and metformin tabldts glipizide er, glipizide and metformin tablrts glipizide er, glipizide and metformin tabl4ts glipizide er, glipizide and metformin tabl3ts glipizide er, glipizide and metformin tablers glipizide er, glipizide and metformin tablefs glipizide er, glipizide and metformin tablegs glipizide er, glipizide and metformin tableys glipizide er, glipizide and metformin table6s glipizide er, glipizide and metformin table5s glipizide er, glipizide and metformin tableta glipizide er, glipizide and metformin tabletz glipizide er, glipizide and metformin tabletx glipizide er, glipizide and metformin tabletd glipizide er, glipizide and metformin tablete glipizide er, glipizide and metformin tabletw glipizide er, glipizide and metformin tablets flipizide er, glipizide and metformin tablets vlipizide er, glipizide and metformin tablets blipizide er, glipizide and metformin tablets hlipizide er, glipizide and metformin tablets ylipizide er, glipizide and metformin tablets tlipizide er, glipizide and metformin tablets gkipizide er, glipizide and metformin tablets gpipizide er, glipizide and metformin tablets goipizide er, glipizide and metformin tablets glupizide er, glipizide and metformin tablets gljpizide er, glipizide and metformin tablets glkpizide er, glipizide and metformin tablets glopizide er, glipizide and metformin tablets gl9pizide er, glipizide and metformin tablets gl8pizide er, glipizide and metformin tablets glioizide er, glipizide and metformin tablets glilizide er, glipizide and metformin tablets gli-izide er, glipizide and metformin tablets gli0izide er, glipizide and metformin tablets glipuzide er, glipizide and metformin tablets glipjzide er, glipizide and metformin tablets glipkzide er, glipizide and metformin tablets glipozide er, glipizide and metformin tablets glip9zide er, glipizide and metformin tablets glip8zide er, glipizide and metformin tablets glipixide er, glipizide and metformin tablets glipiside er, glipizide and metformin tablets glipiaide er, glipizide and metformin tablets glipizude er, glipizide and metformin tablets glipizjde er, glipizide and metformin tablets glipizkde er, glipizide and metformin tablets glipizode er, glipizide and metformin tablets glipiz9de er, glipizide and metformin tablets glipiz8de er, glipizide and metformin tablets glipizise er, glipizide and metformin tablets glipizixe er, glipizide and metformin tablets glipizice er, glipizide and metformin tablets glipizife er, glipizide and metformin tablets glipizire er, glipizide and metformin tablets glipiziee er, glipizide and metformin tablets glipizidw er, glipizide and metformin tablets glipizids er, glipizide and metformin tablets glipizidd er, glipizide and metformin tablets glipizidr er, glipizide and metformin tablets glipizid4 er, glipizide and metformin tablets glipizid3 er, glipizide and metformin tablets glipizide wr, glipizide and metformin tablets glipizide sr, glipizide and metformin tablets glipizide dr, glipizide and metformin tablets glipizide rr, glipizide and metformin tablets glipizide 4r, glipizide and metformin tablets glipizide 3r, glipizide and metformin tablets glipizide ee, glipizide and metformin tablets glipizide ed, glipizide and metformin tablets glipizide ef, glipizide and metformin tablets glipizide et, glipizide and metformin tablets glipizide e5, glipizide and metformin tablets glipizide e4, lipizide and metformin tablets glipizide er, gipizide and metformin tablets glipizide er, glpizide and metformin tablets glipizide er, gliizide and metformin tablets glipizide er, glipzide and metformin tablets glipizide er, glipiide and metformin tablets glipizide er, glipizde and metformin tablets glipizide er, glipizie and metformin tablets glipizide er, glipizid and metformin tablets glipizide er, glipizideand metformin tablets glipizide er, glipizide nd metformin tablets glipizide er, glipizide ad metformin tablets glipizide er, glipizide an metformin tablets glipizide er, glipizide andmetformin tablets glipizide er, glipizide and etformin tablets glipizide er, glipizide and mtformin tablets glipizide er, glipizide and meformin tablets glipizide er, glipizide and metormin tablets glipizide er, glipizide and metfrmin tablets glipizide er, glipizide and metfomin tablets glipizide er, glipizide and metforin tablets glipizide er, glipizide and metformn tablets glipizide er, glipizide and metformi tablets glipizide er, glipizide and metformintablets glipizide er, glipizide and metformin ablets glipizide er, glipizide and metformin tblets glipizide er, glipizide and metformin talets glipizide er, glipizide and metformin tabets glipizide er, glipizide and metformin tablts glipizide er, glipizide and metformin tables glipizide er, glipizide and metformin tablet glipizide er, glipizide and metformin tablets glipizide er, glipizide and metformin tablets glipizide er, glipizide and metformin tablets lipizide er, glipizide and metformin tablets gipizide er, glipizide and metformin tablets glpizide er, glipizide and metformin tablets gliizide er, glipizide and metformin tablets glipzide er, glipizide and metformin tablets glipiide er, glipizide and metformin tablets glipizde er, glipizide and metformin tablets glipizie er, glipizide and metformin tablets glipizid er, glipizide and metformin tablets glipizideer, glipizide and metformin tablets glipizide r, glipizide and metformin tablets glipizide e, lgipizide and metformin tablets glipizide er, gilpizide and metformin tablets glipizide er, glpiizide and metformin tablets glipizide er, gliipzide and metformin tablets glipizide er, glipziide and metformin tablets glipizide er, glipiizde and metformin tablets glipizide er, glipizdie and metformin tablets glipizide er, glipizied and metformin tablets glipizide er, glipizid eand metformin tablets glipizide er, glipizidea nd metformin tablets glipizide er, glipizide nad metformin tablets glipizide er, glipizide adn metformin tablets glipizide er, glipizide an dmetformin tablets glipizide er, glipizide andm etformin tablets glipizide er, glipizide and emtformin tablets glipizide er, glipizide and mteformin tablets glipizide er, glipizide and meftormin tablets glipizide er, glipizide and metofrmin tablets glipizide er, glipizide and metfromin tablets glipizide er, glipizide and metfomrin tablets glipizide er, glipizide and metforimn tablets glipizide er, glipizide and metformni tablets glipizide er, glipizide and metformi ntablets glipizide er, glipizide and metformint ablets glipizide er, glipizide and metformin atblets glipizide er, glipizide and metformin tbalets glipizide er, glipizide and metformin talbets glipizide er, glipizide and metformin tabelts glipizide er, glipizide and metformin tabltes glipizide er, glipizide and metformin tablest glipizide er, glipizide and metformin tablet s glipizide er, glipizide and metformin tablets glipizide er, glipizide and metformin tablets g lipizide er, glipizide and metformin tablets lgipizide er, glipizide and metformin tablets gilpizide er, glipizide and metformin tablets glpiizide er, glipizide and metformin tablets gliipzide er, glipizide and metformin tablets glipziide er, glipizide and metformin tablets glipiizde er, glipizide and metformin tablets glipizdie er, glipizide and metformin tablets glipizied er, glipizide and metformin tablets glipizid eer, glipizide and metformin tablets glipizidee r, glipizide and metformin tablets glipizide re, gglipizide and metformin tablets glipizide er, gllipizide and metformin tablets glipizide er, gliipizide and metformin tablets glipizide er, glippizide and metformin tablets glipizide er, glipiizide and metformin tablets glipizide er, glipizzide and metformin tablets glipizide er, glipiziide and metformin tablets glipizide er, glipizidde and metformin tablets glipizide er, glipizidee and metformin tablets glipizide er, glipizide and metformin tablets glipizide er, glipizide aand metformin tablets glipizide er, glipizide annd metformin tablets glipizide er, glipizide andd metformin tablets glipizide er, glipizide and metformin tablets glipizide er, glipizide and mmetformin tablets glipizide er, glipizide and meetformin tablets glipizide er, glipizide and mettformin tablets glipizide er, glipizide and metfformin tablets glipizide er, glipizide and metfoormin tablets glipizide er, glipizide and metforrmin tablets glipizide er, glipizide and metformmin tablets glipizide er, glipizide and metformiin tablets glipizide er, glipizide and metforminn tablets glipizide er, glipizide and metformin tablets glipizide er, glipizide and metformin ttablets glipizide er, glipizide and metformin taablets glipizide er, glipizide and metformin tabblets glipizide er, glipizide and metformin tabllets glipizide er, glipizide and metformin tableets glipizide er, glipizide and metformin tabletts glipizide er, glipizide and metformin tabletss glipizide er, glipizide and metformin tablets glipizide er, glipizide and metformin tablets glipizide er, glipizide and metformin tablets gglipizide er, glipizide and metformin tablets gllipizide er, glipizide and metformin tablets gliipizide er, glipizide and metformin tablets glippizide er, glipizide and metformin tablets glipiizide er, glipizide and metformin tablets glipizzide er, glipizide and metformin tablets glipiziide er, glipizide and metformin tablets glipizidde er, glipizide and metformin tablets glipizidee er, glipizide and metformin tablets glipizide er, glipizide and metformin tablets glipizide eer, glipizide and metformin tablets glipizide err, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved